Funding for this research was provided by:
cancer immunotherapy research institute (Not applicable)
rcu labs, inc. (Not applicable)
Received: 28 June 2021
Accepted: 24 June 2022
First Online: 7 July 2022
: This study was approved by the Cancer Immunotherapy Research Institute IRB, Federal Wide Assurance number FWA00029851. Written informed consent was obtained from all subjects prior to their participation, and a copy of the signed informed consent form was provided to each subject.
: Not applicable.
: The authors declare that they have no competing interests.